Merck's (MRK) Strong Keytruda Data in NSCLC Raises Bar for Bristol-Myers (BMY), Others - Leerink
Tweet Send to a Friend
Leerink is out with commentary on Keytruda after Merck (NYSE: MRK) announced that the drug delivered a benefit on both ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
